论文部分内容阅读
30例原发性轻～中度高血压患者(男23人,女7人,平均年龄52岁,范围36～65岁)行双盲交叉试验。病人随机接受含药200mg;的美多心安缓释片,联合安慰荆或氯噻酮25mg每天1次。分别记录用药前24～48小时以及用药后2个月内每例病人不卧床的动脉血压,在相同的记录期间内测量血压和脉率对标准运动(包括仰卧静息、握力和脚力车)的反应。治疗可明显地减少血压与脉率。接受美多心安联合安慰剂的病人组(美安组),其平均动脉压从治疗前的174/95mmHg下降到治疗后的158/85mmHg,接受美多心安联合氯噻酮的病人组(美氯组),其平均动脉压减低到143/78mmHg,后者的减低数明显大于前
30 patients with primary mild to moderate hypertension (23 males and 7 females, mean age 52 years, range 36 to 65 years) double-blind cross-test. The patient was randomized to receive a drug containing 200 mg of Melaleucaol Sustained-release Tablets, in combination with a placebo or chlorthalidone 25 mg once daily. Blood pressure and pulse rate were measured during standard recording sessions (including supine rest, grip, and rickshaws) during the same recording period for 24 to 48 hours prior to and within 2 months of treatment, respectively reaction. Treatment can significantly reduce blood pressure and pulse rate. The mean arterial pressure of patients receiving metoprolol in combination with placebo decreased from 174 / 95mmHg before treatment to 158/85 mmHg after treatment. The patients receiving metomustine plus chlorthalidone Group), the mean arterial pressure was reduced to 143 / 78mmHg, the latter reduction was significantly greater than the former